Dr Reddy's Share Price Surges on Partner with Alvotech to Co-Develop Biosimilar to Keytruda

On 5 June 2025, Alvotech, a global biotech company specialising in biosimilars, and Dr. Reddy’s Laboratories Ltd., a leading pharmaceutical firm from India, announced a strategic collaboration. The companies will jointly develop, manufacture, and commercialise a biosimilar candidate to Keytruda (pembrolizumab), a key therapy in immuno-oncology with global sales of $29.5 billion in 2024. This move reinforces both companies’ commitment to broadening access to biologic medicines across the world.

Dr Reddy’s and Alvotech: A Global Collaboration in Biosimilars

The partnership is structured through a collaboration and a licence agreement. Both Dr Reddy’s and Alvotech will jointly undertake development and manufacturing responsibilities while sharing associated costs. Subject to specific exceptions, each company will also hold the right to commercialise the biosimilar globally. This project targets Keytruda®, one of the most widely used cancer immunotherapies.

Alvotech’s chairman and CEO, Róbert Wessman, stated, “This agreement demonstrates Alvotech’s ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets.” His remarks reflect Alvotech’s objective to provide high-quality and affordable biologics worldwide.

Dr. Reddy’s Strategic Focus on Oncology and Global Expansion

Dr Reddy’s Laboratories has been strengthening its biologics division over the last 25 years. With several biosimilars already marketed in over 30 countries and additional products in the pipeline, the company is committed to addressing unmet medical needs. Erez Israeli, CEO of Dr. Reddy’s, noted, “This demonstrates our ability to develop and manufacture high-quality and affordable treatment options for patients worldwide... this collaboration will further enhance our capabilities in oncology.”

In 2024, Dr Reddy’s launched its first biosimilar in the United Kingdom, Versavo (biosimilar bevacizumab), following earlier launches in the U.S. and Europe through partnerships. This biosimilar venture with Alvotech further positions the company to expand its reach in developed and emerging markets alike.

Read More: Dr Reddy’s Laboratories Posts FY25 Results!

Dr Reddy's Share Price Performance 

As of June 05, 2025, at 11:30 AM, Dr Reddy share price is trading at ₹1,286.60 per share, reflecting a decline of 2.77% from the previous closing price. Over the past month, it has declined by 9.84%.

Conclusion

The collaboration between Alvotech and Dr Reddy’s Laboratories marks a strategic milestone in the global biosimilar landscape. By combining Alvotech’s robust manufacturing capabilities with Dr Reddy’s commercial and therapeutic expertise in oncology, the partnership aims to make life-saving biologics like pembrolizumab more accessible and affordable to patients around the world.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.